ArticleThe Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale2026
Seroprevalence of Coronavirus NL63 in Yamagata, Japan, Between 1976 and 2022.
Article in The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Seroprevalence of Coronavirus NL63 in Yamagata, Japan, Between 1976 and 2022.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advances in the epidemiology of seasonal coronavirus (CoV) are important for understanding CoV transmission dynamics and strengthening the strategies against emerging CoV infections. The epidemiology of CoV-NL63, a seasonal CoV discovered in 2003, is poorly understood, particularly before 2003. To analyze the seroprevalence of CoV-NL63 in Yamagata, Japan, we performed a microneutralization test using 146 to 379 serum samples collected from four age groups ranging from 0 to 4 years to ≥ 40 years in 1976, 1990, 2010, 2019, and 2022, as well as the Yamagata isolate. We only measured the neutralizing antibodies (NT Abs) against CoV-NL63, as methods for other seasonal CoVs had not yet been established. The total NT Ab-positive rate in each year was 68.0%-90.4%. The Ab-positive rates in 0-4-year age group were 21.3%-65.2% in each year, whereas the rates for individuals aged above 4 years old were between 73.3% and 100% throughout the study period. We do not understand the influence of cross-reactive immunity among seasonal CoVs. This study shows that seroprevalence against CoV-NL63 increased with age in the younger generation and then plateaued at a high level, suggesting that reinfection may occur and that CoV-NL63 was already transmitted among infants and children before CoV-NL63 had been identified.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.